With this wealth of supporting data concerning ACTG2 variants in association with VM phenotype,s we recommend a change in the nomenclature for these patients to ‘autosomal dominant ACTG2 visceral myopathy’. This evidence concerns the gene ACTG2 and familial visceral myopathy.